← Back to Search

Vasodilator

Angiotensin 1-7 for Peripheral Arterial Disease

Phase < 1
Waitlist Available
Led By Amy C Arnold, PhD
Research Sponsored by Milton S. Hershey Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 50 minutes
Awards & highlights

Study Summary

This trial will test whether or not the hormone angiotensin-(1-7) can help treat peripheral arterial disease by improving blood vessel function and reducing inflammation.

Eligible Conditions
  • Peripheral Arterial Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~50 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 50 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Tumor Markers
Leg Blood Flow
Secondary outcome measures
Blood Pressure
Heart Rate
Other outcome measures
Lipids
Nitric Oxide Bioavailability
Renin-Angiotensin System Hormones

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Angiotensin-(1-7)Experimental Treatment1 Intervention
Subjects will receive intravenous infusion of five ascending doses of angiotensin-(1-7). The doses are: 1, 2, 4, 8, and 12 ng/kg/min. Each dose will be maintained for 10 minutes, for a total infusion period of 50 minutes.
Group II: SalinePlacebo Group1 Intervention
Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7) arm. Saline infusion will be maintained for a total infusion period of 50 minutes.

Find a Location

Who is running the clinical trial?

Milton S. Hershey Medical CenterLead Sponsor
492 Previous Clinical Trials
2,798,816 Total Patients Enrolled
5 Trials studying Peripheral Arterial Disease
327 Patients Enrolled for Peripheral Arterial Disease
Amy C Arnold, PhDPrincipal InvestigatorPenn State College of Medicine
2 Previous Clinical Trials
56 Total Patients Enrolled

Media Library

Angiotensin 1-7 (Vasodilator) Clinical Trial Eligibility Overview. Trial Name: NCT03240068 — Phase < 1
Peripheral Arterial Disease Research Study Groups: Saline, Angiotensin-(1-7)
Peripheral Arterial Disease Clinical Trial 2023: Angiotensin 1-7 Highlights & Side Effects. Trial Name: NCT03240068 — Phase < 1
Angiotensin 1-7 (Vasodilator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03240068 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment recruiting new participants at the moment?

"According to clinicaltrials.gov, this particular medical trial is not presently recruiting new participants as the latest update was on December 1st 2022. Nonetheless, there are 340 other experiments that have vacancies at present."

Answered by AI

Am I eligible to become a participant in this experiment?

"Those hoping to join this clinical trial must have peripheral arterial disease and be aged between 21 and 80. Unfortunately, space is limited as only 6 patients will be accepted."

Answered by AI

Does the protocol of this trial encompass participants aged 70 or greater?

"This particular medical study is accepting candidates over the age of majority and younger than 80 years old."

Answered by AI

For what ailments is Angiotensin 1-7 often prescribed?

"Angiotensin 1-7 has been proven to remedy issues associated with hemodilution, caloric deficiency, and potassium depletion."

Answered by AI

Has research revealed any prior experiments concerning Angiotensin 1-7?

"At present, 124 research studies concerning the drug Angiotensin 1-7 are underway. 33 of these ongoing experiments have reached Phase 3 and 867 medical centres across Canada are participating in them; Calgary being one of the main sites for such trials."

Answered by AI

How many volunteers has this trial recruited thus far?

"At present, no further participants are being sought for this particular experiment which was initially posted on September 1st 2017 and most recently updated in December 2022. For those interested in similar research studies, 216 medical trials with relevance to peripheral arterial disease are presently recruiting patients while 124 Angiotensin 1-7 related experiments require subjects as well."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Angiotensin-(1-7) in Peripheral Arterial Disease
Amy Arnold 2017. "Angiotensin-(1-7) in Peripheral Arterial Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03240068.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top